Hostname: page-component-6766d58669-tq7bh Total loading time: 0 Render date: 2026-05-17T23:12:15.916Z Has data issue: false hasContentIssue false

Clinicopathological features of mucoepidermoid carcinoma

Published online by Cambridge University Press:  22 January 2014

K Yamazaki*
Affiliation:
Niigata Prefecture Head and Neck Malignant Tumour Registration Committee, Faculty of Medicine, Niigata University, Japan Department of Otorhinolaryngology, Faculty of Medicine, Niigata University, Japan
H Ohta
Affiliation:
Niigata Prefecture Head and Neck Malignant Tumour Registration Committee, Faculty of Medicine, Niigata University, Japan Department of Otorhinolaryngology, Faculty of Medicine, Niigata University, Japan
R Shodo
Affiliation:
Niigata Prefecture Head and Neck Malignant Tumour Registration Committee, Faculty of Medicine, Niigata University, Japan Department of Otorhinolaryngology, Faculty of Medicine, Niigata University, Japan
H Matsuyama
Affiliation:
Niigata Prefecture Head and Neck Malignant Tumour Registration Committee, Faculty of Medicine, Niigata University, Japan Department of Otorhinolaryngology, Faculty of Medicine, Niigata University, Japan
S Takahashi
Affiliation:
Niigata Prefecture Head and Neck Malignant Tumour Registration Committee, Faculty of Medicine, Niigata University, Japan Department of Otorhinolaryngology, Faculty of Medicine, Niigata University, Japan
*
Address for correspondence: Dr Keisuke Yamazaki, Department of Otorhinolaryngology, Faculty of Medicine, Niigata University, 1-757 Asahimachi-dori, Chuo-ku, Niigata-shi 951-8510, Japan Fax: +81 025 227 0786 E-mail: bymyself@med.niigata-u.ac.jp

Abstract

Objective:

We aimed to examine the clinical usefulness of a new World Health Organization classification scheme for salivary gland mucoepidermoid carcinoma, and to identify the factors most strongly associated with prognosis and outcome.

Methods:

The clinicopathological features of 45 patients who received treatment for mucoepidermoid carcinoma between 1986 and 2010 were retrospectively investigated.

Results:

The overall disease-specific 5-year survival rate was 81.8 per cent. The rate for patients with low-grade tumours (92.5 per cent) was significantly higher than that for patients with intermediate or high-grade tumours (52.2 per cent). Univariate analysis revealed that five factors were significantly associated with five-year survival: age, tumour stage classification, lymph node status, histological grade and treatment method. Four factors were significant in multivariate analysis: age, sex, tumour stage classification and lymph node status.

Conclusion:

The new World Health Organization classification was useful in predicting disease progression in patients with mucoepidermoid carcinoma. Patients with high-grade tumours or other prognostic factors positively associated with disease progression should be carefully evaluated and monitored.

Information

Type
Main Articles
Copyright
Copyright © JLO (1984) Limited 2014 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Article purchase

Temporarily unavailable